

# Dual High Flow Oxygen Therapy and CPAP Ventilation in a Single Device for COVID-19

James Kelly, Michael Dowe, Jonathan Briggs, Michael Chan, Juan F. Martin-Lazaro  
*Intensive Care Unit, Newham University Hospital, London.*  
[juan.martinlazaro@nhs.net](mailto:juan.martinlazaro@nhs.net)

## ABSTRACT

High flow oxygen therapy (HFOT) and Continuous positive airway pressure (CPAP) could be considered the most important ventilatory therapies during the COVID-19 pandemic because of their frequency of use. There are many devices on the market which provide this type of ventilatory support, and these should be distinguished from one another by their efficacy, versatility, patient comfort, hygiene and cost. We evaluated the AquaVENT FD140i from Armstrong Medical, which delivers both HFOT and CPAP, concluding that it provides two potentially efficacious treatments to COVID-19 patients, while its long-life battery facilitates transfers for escalation and de-escalation of care. We compared the AquaVENT FD140i with the Fisher & Paykel MR850, which is a gold standard in the market. We also looked at the compatibility of their humidifier and disposables with Armstrong Medical devices. The results of this study suggest the compatibility of both systems, which has the potential to reduce consumable costs.

**Keywords:** COVID-19, HFOT, CPAP, dual therapy, flow driver, humidifier

## 1 Introduction

High flow oxygen therapy (HFOT) is a method of non-invasive oxygen delivery, in which humidified air-oxygen blends can be delivered at up to 60 L/min, and the fraction of inspired oxygen can be titrated up to 100% [1]. Continuous positive airway pressure (CPAP) delivers continuous positive airway pressures through either a face mask, a nasal mask or a helmet [2].

The role of HFOT and CPAP in the treatment of Coronavirus Disease 2019 (COVID-19) is incompletely characterised, since the identification of those patients who require intubation is a subject of ongoing controversy [3]. Some patients can be managed well with supplemental oxygen, although those with the most severe respiratory failure clearly require the insertion of an endotracheal tube [4,5].

It has been postulated that COVID-19 comprises two main phenotypes, although this is currently debated [6–8]. ‘L’, or ‘non-ARDS’, is characterised by high compliance and the loss of reactive hypoxic vasoconstriction, which can lead to a ventilation perfusion mismatch [6,8]. The ‘H’, or ‘ARDS’, phenotype is characterised by pulmonary oedema which progresses to consolidation [6,8]. The L phenotype may respond well to non-invasive ventilation, and the H phenotype to invasive ventilation, with high positive end-expiratory pressures and low tidal volumes [9].

---

DOI: 10.14738/jbemi.76.9324

Publication Date: 06<sup>th</sup> February 2021

URL: <http://dx.doi.org/10.14738/jbemi.76.9324>

Invasive and non-invasive ventilation carry with them different risks. The placement of an endotracheal tube allows control over a threatened or unstable airway, and permits the tight regulation of oxygenation and ventilation [10]. However, the placement of the tube is associated with a wide range of potential complications [11]. Furthermore, as mechanical ventilation increases in duration, morbidity and mortality also increases [12].

Non-invasive ventilation, such as HFOT and CPAP, avoids the risks associated with intubation. However, it has been suggested that non-invasive ventilation may lead to greater spread of COVID-19 to healthcare workers compared to invasive ventilation. This has not been borne out by a number of experimental and observational studies, although few have directly compared aerosol dispersal from HFOT and CPAP with invasive ventilation [13]. Nevertheless, a number of studies comparing aerosol dispersion from HFOT and CPAP with that from conventional oxygen therapy have shown no statistically significant increase in dispersal with these therapies [14]. Studies which attempt to quantify dispersal have found that it is limited to the patient's face and the CPAP mask or HFOT cannulae themselves [15].

The potential efficacy of HFOT in COVID-19 can be inferred from its efficacy in other severe viral respiratory illnesses like influenza A and H1N1 [16]. Use of HFOT has led to lower progression to invasive ventilation compared with other forms of non-invasive oxygen therapy across a number of respiratory pathologies [17]. In COVID-19 patients, a number of recent studies have suggested that HFOT use is associated with a reduction in the rate of invasive mechanical ventilation and overall mortality in patients with moderate to severe hypoxaemic respiratory failure [18].

CPAP also has a substantial evidence base for its efficacy as a supportive treatment for patients in type 1 respiratory failure [19]. Despite initial concerns regarding its use in COVID-19, early anecdotal experience has been favourable with newer guidelines now suggesting CPAP as an option for care [20].

## 2 Aims

- To evaluate the AquaVENT FD104i flow driver's potential benefits and utility in the COVID-19 pandemic.
- To evaluate the AquaVENT 2600A humidifier and circuits as potential adjuncts to the AquaVENT FD104i by testing airway and circuit temperatures with varying flow rate and comparing them to industry gold standard humidifier and circuits from Fisher & Paykel.

## 3 The AquaVENT FD140i Flow Driver

The AquaVENT FD140i is a dual therapy flow driver, that incorporates an external humidifier, the AquaVENT 2600A, which allows for patients to be switched between HFOT and CPAP quickly and simply. It can be used for adult, paediatric and neonatal patients. CPAP options include Facemask CPAP, Helmet CPAP and Bubble PAP.

The AquaVENT FD140i has six modes of use: CPAP, CPAP paediatric CPAP, CPAP Helmet, Bubble PAP, HFOT and POINT. It has a maximum CPAP flow rate of 140L/min, and a maximum HFOT flow rate of 70L/min. It has an integrated drug nebuliser. Anti-microbial hosing can be supplied. The internal battery maintains an hour charge, and has a low charge alarm. The alarm system has two-tier visual and aural alarms, and include pressure and apnoea alarms. It has a 7-inch, high resolution multi-colour LCD touch-screen. Setting adjustments can be made in single digit increments for flow rate and FiO<sub>2</sub>.

A sensitive respiratory wave highlights patients’ work of breathing and assists with setting optimal flow rates. This is potentially of great benefit, since delivering CPAP requires optimising flow to meet the patient’s peak inspiratory requirement. The visual representation of respiratory rate and wave form allows clinicians to evaluate the patient’s response to CPAP more easily.

Patients who require a treatment escalation from HFOT to CPAP, or those who are ready to wean from CPAP to HFOT, can have their treatment delivered through a single machine. This has attendant benefits in terms of patient comfort and reduced consumable costs. The long-life battery facilitates patient transfers, for example from a medical ward to an intensive care unit. In addition, the flow driver is quiet, with consequent benefits to patients and attending staff. Additionally, the AquaVENT FD140i can be used with a dedicated helmet CPAP mode with minimum flow of 40L to prevent CO2 rebreathing and it provides a barrier of protection for healthcare workers from COVID-19 aerosolization.

#### 4 Methods

A test was performed with two humidifiers, the AquaVENT 2600A and the Fisher Paykel MR850. The AquaVENT 2600A has two temperature modes displayed on screen: invasive, which delivers 40°C at the end of the breathing circuit, and non-invasive, that delivers 34°C at the end of the breathing circuit. This temperature monitoring provides a second check to the humidity - temperature measurements.

The gas source was at 6 bar for medical air and oxygen, setting a constant FiO<sub>2</sub> of 40%. The gas inflow was at 23°C, and for CPAP analysis a Positive End Expiratory Pressure (PEEP) of 10 cmH<sub>2</sub>O was set. Ambient temperature was 22°C [-1 to +2] at 30 – 50% humidity. Ambient air speed was less than 5 cm.s at 1 atmosphere. The stabilisation time of the devices was 60 minutes and the data collection point was done after 90 minutes. Humidity and temperature was measured with a DM509-TX-01 (Rense Instruments, Oosterhout, NL). The breathing circuits were Armstrong Medical REFs AMHO1509/008 and AMCKUK01240 and Fisher Paykel Healthcare RT202. Measures were taken three times, and the average recorded.

#### 5 Results


Temperature decrease with the Fisher & Paykel MR850 takes place in direct proportion to the increase of gas flow. This can be seen in Table 1. This variation takes place above 40L of gas flow either at the airway or the chamber for both types of consumables. Temperature alarms are triggered over 70L in the airway or over 50L in the chamber. The difference between consumable temperatures is maximum at 40L with decrease of 1.0°C when using the Armstrong Airway and -0.3°C at flows of 90L in the airway or 40L in the chamber.

**Table 1. Temperature/Gas Flow variation with Heater F&P-MR850**

Heater: F&P-MR850	Gas Flow Rate [L/min]						
	30	40	50	60	70	80	90
Armstrong Airway T [°C]	40.0	39.0	39.2	39.0	37.2	36.1	34.7
F&P Airway T [°C]	40.0	40.0	39.3	39.0	37.4	36.2	35.0
Armstrong Chamber T [°C]	37.0	36.5	35.5	34.4	32.1	30.0	29.0
F&P Chamber T [°C]	37.0	36.8	35.5	34.1	32.1	29.9	29.1

Low Chamber Temperature Alarm  
 Low Airway Temperature Alarm

In the following graph (Graph 1) temperatures maintain a homogenous variation with the heater F&P-MR850 either in the airway circuit or the chamber.



**Graph 1. Temperature/Gas Flow variation with Heater F&P-MR850**

When the AquaVENT 2600A is used, the temperature decreases at high flows (90L) in the airway for the Fisher & Paykel Airway of -0.8°C, and -0.5°C in the Fisher & Paykel Chamber. Temperature varies in indirect proportion to increase in flow rates. This appears more stable than with the Fisher & Paykel MR580 heater. Temperature alarms are triggered at flows of 80L in the airway or at 60L in the chamber; a difference of 10L of flow when compared with the heater Fisher & Paykel MR850.


**Table 2. Temperature/Gas Flow variation with Heater AquaVENT 2600A**

Heater: Arms 2600A	Gas Flow Rate [L/min]						
	30	40	50	60	70	80	90
Armstrong Airway T [°C]	40.0	40.0	39.5	39.1	37.6	37.0	36.0
F&P Airway T [°C]	40.0	40.0	39.3	39.0	37.5	36.8	35.2
Armstrong Chamber T [°C]	37.0	36.8	36.1	34.6	33.6	32.0	30.0
F&P Chamber T [°C]	37.0	36.8	36.1	34.6	33.6	32.0	29.5

- Low Chamber Temperature Alarm
- Low Airway Temperature Alarm

This stability can be observed in the graph below (Graph 2), in which there is a maximum temperature difference of -0.8°C in the Fisher & Paykel Airway Circuit or -0.5°C for Fisher & Paykel chamber.

Graph 2. Temperature/Gas Flow variation with Heater AquaVENT 2600A



## 6 Discussion

Non-invasive ventilation (NIV) therapies with interfaces such as a helmet or a face mask do not require humidification temperature of greater than 34°C for patient comfort. However, HFOT via nasal cannulae or through a tracheostomy, or CPAP through a tracheostomy, may require a higher temperature setting for patient comfort and to optimise therapy. In these contexts, it is potentially of benefit to use the AquaVENT FD140i driver and AquaVENT 2600A humidifier. This appears to be more temperature stable in high flows over 50L, maintaining temperatures closer to 40°C to higher flow rates.

Consequently, alarms are not triggered as quickly, since the AquaVENT 2600A is better able to achieve the temperatures within the desired range. It may be the case that the Fisher and Paykel humidifier was not manufactured to work at flows greater than 50-60L, which are the maximum flows achievable with F&P device. Variations between both systems may be related to the geometry of the chamber or the kinetic forces in the circuit but, even at flows of 90L, optimal results appear to be obtained with the combination of the AquaVENT humidifier and Armstrong circuit.

These results also appear to demonstrate that these two circuits are compatible with one another. During the COVID-19 pandemic, a great number of hospitals across the world were forced by depleted stocks to use whatever disposable materials were available, regardless of manufacturer. Therefore, it is relevant to healthcare providers to know the performance of ventilatory equipment with different disposable materials.

## 7 Conclusions

Current evidence suggests that HFOT and CPAP are efficacious in the treatment of COVID-19. The advantage of dual therapy in one device plus and integrated nebuliser is that, apart from patient comfort,

the patient may be able to remain connected to the device for longer periods, with consequent maintenance of oxygenation.

Dual therapy may also be associated with reduced healthcare costs. The ease of escalation and weaning with a single device may help reduce ICU length of stay, or potentially avoid admission. Consumable costs will also be lower. A single circuit may be used for both HFOT and CPAP, and potentially reduce therapy costs by up to 50%.

Consequently, the AquaVENT FD140i provides two potentially efficacious treatments to COVID-19 patients in invasive mode (40°C) at high range of flows, while its long-life battery facilitates transfers for escalation and de-escalation of care. Furthermore, the AquaVENT 2600A compares well to an industry standard humidifier, with better temperature control at higher flow rates. This is particularly evident when paired with an Armstrong circuit, but humidifiers and circuits examined appeared to be compatible with one another.

In summary, the combination of AquaVENT FD140i, AquaVENT 2600A and Armstrong breathing circuit can be expected to be of therapeutic use in COVID-19.

#### ACKNOWLEDGMENTS

We appreciate the help of Armstrong Engineering and Technical Department for obtaining the measurements in these devices.

#### REFERENCES

- [1] Sharma S, Danckers M, Sanghavi D, Chakraborty RK. High Flow Nasal Cannula. StatPearls. StatPearls Publishing; 2020
- [2] Pinto VL, Sharma S. Continuous Positive Airway Pressure (CPAP). StatPearls. StatPearls Publishing; 2020
- [3] Tobin MJ, Laghi F, Jubran A. Caution about early intubation and mechanical ventilation in COVID-19. Vol. 10, *Annals of Intensive Care*. Springer; 2020. p. 78
- [4] Tobin MJ. Basing respiratory management of COVID-19 on physiological principles. Vol. 201, *American Journal of Respiratory and Critical Care Medicine*. American Thoracic Society; 2020. p. 1319–20.
- [5] Yao W, Wang T, Jiang B, Gao F, Wang L, Zheng H, et al. Emergency tracheal intubation in 202 patients with COVID-19 in Wuhan, China: lessons learnt and international expert recommendations. *Br J Anaesth*. 2020 Jul 1;125[1]:e28–37.
- [6] Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. COVID-19 does not lead to a “typical” acute respiratory distress syndrome. Vol. 201, *American Journal of Respiratory and Critical Care Medicine*. American Thoracic Society; 2020. p. 1299–300.
- [7] Fowler AJ, Wan YI, Carenzo L, Haines RW. COVID-19 phenotypes and potential harm of conventional treatments: How to prove the hypothesis. Vol. 202, *American Journal of Respiratory and Critical Care Medicine*. American Thoracic Society; 2020. p. 619–21.

- [8] Jain A, Doyle DJ. Stages or phenotypes? A critical look at COVID-19 pathophysiology. Vol. 46, Intensive Care Medicine. Springer; 2020. p. 1494–5.
- [9] Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Vol. 46, Intensive Care Medicine. Springer; 2020. p. 1099–102.
- [10] Tobin MJ, Laghi F, Jubran A. Ventilatory failure, ventilator support, and ventilator weaning. Vol. 2, Comprehensive Physiology. Compr Physiol; 2012. p. 2871–921.
- [11] Higgs A, McGrath BA, Goddard C, Rangasami J, Suntharalingam G, Gale R, et al. Guidelines for the management of tracheal intubation in critically ill adults. Br J Anaesth. 2018 Feb 1; 120[2]:323–52.
- [12] Kalanuria AA, Zai W, Mirski M. Ventilator-associated pneumonia in the ICU. Vol. 18, Critical Care. BioMed Central Ltd.; 2014
- [13] Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. Vol. 55, The European respiratory journal. NLM; 2020
- [14] Iwashyna TJ, Boehman A, Capelcelatro J, Cohn A, Cooke J, Costa DK, et al. Variation in Aerosol Production Across Oxygen Delivery Devices in Spontaneously Breathing Human Subjects. medRxiv. 2020 Apr 20
- [15] Kotoda M, Hishiyama S, Mitsui K, Tanikawa T, Morikawa S, Takamino A, et al. Assessment of the potential for pathogen dispersal during high-flow nasal therapy. J Hosp Infect. 2020 Apr 1;104[4]:534–7.
- [16] Rello J, Pérez M, Roca O, Poulakou G, Souto J, Laborda C, et al. High-flow nasal therapy in adults with severe acute respiratory infection. A cohort study in patients with 2009 influenza A/H1N1v. J Crit Care. 2012 Oct 1;27[5]:434–9.
- [17] Rochweg B, Granton D, Wang DX, Helviz Y, Einav S, Frat JP, et al. High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis. Vol. 45, Intensive Care Medicine. Springer Verlag; 2019. p. 563–72.
- [18] Patel M, Gangemi A, Marron R, Chowdhury J, Yousef I, Zheng M, et al. Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failure. Vol. 7, BMJ Open Respiratory Research. BMJ Publishing Group; 2020. p. e000650.
- [19] Mas A, Masip J. Noninvasive ventilation in acute respiratory failure. Vol. 9, International Journal of COPD. Dove Medical Press Ltd.; 2014. p. 837–52.
- [20] Namendys-Silva SA. Respiratory support for patients with COVID-19 infection. Vol. 8, The Lancet Respiratory Medicine. Lancet Publishing Group; 2020. p. e18.